NCT03347617 2025-09-09
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
OHSU Knight Cancer Institute
Phase 2 Terminated
OHSU Knight Cancer Institute
Stanford University
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
National Institutes of Health Clinical Center (CC)